Genitourinary cancers at ASCO 2027
Jun 4–8, 2027 Chicago, IL ~44k attendees Website
24 organizations at ASCO 2027 present work in genitourinary cancers: 22 drug developers and 2 diagnostics, technology and service companies. 24 of them have their own page in this guide. As of Oct 8, 2026.
Showing 1–19 of 24 organizations
| Organization | ASCO 2027 Attendance |
|---|---|
Accord BioPharma Raleigh, NC | |
Specialty arm of the Intas group marketing the prostate cancer drug Camcevi, lenalidomide, and supportive-care biosimilars such as filgrastim and pegfilgrastim. | Booth Exhibiting at Booth 37073 |
Arcus Biosciences Hayward, CA | |
Clinical-stage biotech with registrational programs in kidney cancer (HIF-2α inhibitor casdatifan) and pancreatic cancer (CD73 inhibitor quemliclustat). | Booth Exhibiting at Booth 32146 |
Astellas Tokyo, Japan | |
Japanese drugmaker with cancer medicines including enzalutamide for prostate cancer, enfortumab vedotin for bladder cancer and zolbetuximab for gastric cancer. | Booth Exhibiting at Booth 15117 |
AVEO Oncology Boston, MA | |
Oncology company, owned by LG Chem, that markets the kidney cancer drug tivozanib (Fotivda) in the US. | Booth Exhibiting at Booth 19023 |
Bayer Leverkusen, Germany | |
Global drugmaker whose cancer medicines include darolutamide and radium-223 for prostate cancer and regorafenib for colorectal and liver cancers. | Booth Exhibiting at Booth 13059 |
Dendreon Pharmaceuticals Seal Beach, CA | |
Maker of Provenge (sipuleucel-T), an autologous cellular immunotherapy for prostate cancer, and a cell therapy manufacturing services provider. | Booth Exhibiting at Booth 17143 |
Eisai Tokyo, Japan | |
Japanese drugmaker whose cancer medicines include lenvatinib, used in thyroid, liver, kidney and endometrial cancers, and eribulin for breast cancer. | Booth Exhibiting at Booth 19093 |
EMD Serono (Merck KGaA) Boston, MA | |
Healthcare business of Germany's Merck KGaA, with EMD Serono's cancer medicines for colorectal, bladder and lung cancer and SpringWorks' rare tumor drugs. | Booth Exhibiting at Booth 23093 |
enGene Boston, MA | |
Clinical-stage company developing non-viral genetic medicines delivered into the bladder, starting with non-muscle invasive bladder cancer. | Booth Exhibiting at Booth 25085 |
Exelixis Alameda, CA | |
Oncology drugmaker whose cabozantinib (Cabometyx) treats kidney, liver and thyroid cancers; developing zanzalintinib and other small molecules. | Booth Exhibiting at Booth 27001 Booth Exhibiting at Booth 27059 · Exelixis Medical Affairs |
ImmunityBio Culver City, CA | |
Immunotherapy company marketing Anktiva, an IL-15 agonist for BCG-unresponsive bladder cancer, and developing NK cell therapies and vaccines. | Booth Exhibiting at Booth 23148 |
Ipsen Boulogne-Billancourt, France | |
French specialty drugmaker whose cancer medicines include irinotecan liposome (Onivyde) for pancreatic cancer and treatments for neuroendocrine tumors and prostate cancer. | Booth Exhibiting at Booth 11058 |
Johnson & Johnson New Brunswick, NJ | |
Global healthcare company whose Innovative Medicine unit markets cancer drugs for myeloma, lung, prostate and bladder cancers, including daratumumab and amivantamab. | Booth Exhibiting at Booth 15033 |
Lantheus Bedford, MA | |
Radiopharmaceutical company whose products include Pylarify, a PSMA PET imaging agent for prostate cancer, plus therapeutic radioligand programs. | Booth Exhibiting at Booth 17157 |
Novartis Basel, Switzerland | |
Global drugmaker whose cancer medicines include ribociclib for breast cancer, Pluvicto radioligand therapy for prostate cancer and blood cancer treatments. | Booth Exhibiting at Booth 15059, 15078 |
Parabilis Medicines Cambridge, MA | |
Clinical-stage biotech using its Helicon peptide platform against hard-to-drug targets, led by the β-catenin inhibitor zolucatetide, with prostate cancer programs. | Booth Exhibiting at Booth 37115 |
Pfizer New York, NY | |
Global drugmaker whose oncology portfolio spans ADCs from Seagen, small molecules, bispecifics and immunotherapies for breast, prostate, bladder, lung and blood cancers. | Booth Exhibiting at Booth 30071 · Pfizer Oncology |
Predicine Hayward, CA | |
Liquid biopsy company profiling cell-free DNA and RNA from blood, urine or tissue to support biomarker-driven trials for biopharma. | Booth Exhibiting at Booth 19107 |
Sumitomo Pharma America Marlborough, MA | |
US arm of Japan’s Sumitomo Pharma, formed from Sunovion, Myovant, Urovant and other affiliates, with oncology, urology and other programs. | Booth Exhibiting at Booth 25165 |
Instantly find 20 buyers in genitourinary cancers
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Browse ASCO 2027 by
Organization type
Focus
- Clinical trials 58
- Biomarkers and genomics 44
- AI and data 38
- Blood cancers 36
- Lung cancer 28
- Genitourinary cancers 24
- Gastrointestinal cancers 21
- Breast cancer 18
- Immunotherapy 17
- Imaging and radiation 17
- Patient support and survivorship 14
- Antibody-drug conjugates 9
- Cell and gene therapy 8
- Melanoma and skin cancers 7
- Gynecologic cancers 6
Exhibit hall
Everyone
Not affiliated with the American Society of Clinical Oncology. Organization details are derived from ASCO’s published exhibitor list and each exhibitor’s own profile and website. Submit a correction